

Anti-MYOD1 [rMYD712]

Catalog No.	Description
AMA21-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AMA21-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
MUA21-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
MUA21-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AXA21-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests
AXA21-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests

Clone	Species	Ig Class
rMYD712	Mouse	IgG1, Kappa

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of MyoD1 in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

MyoD1, also known as myogenic differentiation 1 or myoblast determination protein 1, plays a major role in regulating muscle differentiation. MyoD1 (45kDa) is a part of the family of myogenic regulatory factors that also include Myf5, Myf6 and Myogenin. MyoD1 is a transcription factor that promotes genes that permit myoblast proliferation. Mice born carrying non-functional mutants of Myf5 and MyoD1 are unable to develop any skeletal muscle and die shortly after birth, implying its importance as a myogenic marker. MyoD1 is responsible for mesodermal cells committing to and maintaining a myogenic lineage. MyoD1 is also responsible for repairing muscles after damage from activity or trauma. MyoD1 arrests the cell cycle in terminally differentiated myoblasts by regulating Cyclin D1.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody MyoD1 is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	Rhabdomyosarcoma tissue as available from BioGenex FB-A21M* & FG-A21M*
Recommended Dilution for Concentrated Antibody	1:10-25 in HK941
Recommended Pretreatment (Manual/i6000)**	EZ-AR1 (HK521-XAK)
Recommended Pretreatment (Xmatrx)	EZ-AR1 (HX031-YCD)
Antibody Incubation (Manual/i6000)	30-60 min at RT
Antibody Incubation (Xmatrx)	30-60 min at 25°C
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx requires micro chamber slides.

**Pretreatment times will vary based on individual microwave power.

***For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	F
Document No.	932-A21M-EN	Release Date	12-Nov-2021

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKE (1000 Test)		
	QD420-YIKE (500 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
	QD400-60KE (60 Test)		
Xmatrix - Automation	QD550-YCDE (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410-YAXE (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit www.biogenex.com .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results









This antibody stains nucleus in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Fong A., Tapscott S. Skeletal muscle programming and re-programming. Current Opinion in genetics and development. 2013 October. 23 (5), 568-73.
- Rajabi H., Takahashi C., Ewen M. Retinoblastoma Protein and MyoD Function Together to Effect the Repression of Fra-1 and in Turn Cyclin D1 During Terminal Cell Cycle Arrest Associated With Myogenesis. The Journal of Biological Chemistry. 2014 August. 289 (34), 23417-27.
- “MYOD1 Myogenic Differentiation 1 [Homo Sapiens (Human)] - Gene - NCBI.” National Center for Biotechnology Information, U.S. National Library of Medicine.
- Rudnicki M., Schlegelsberg P., et al. MyoD or Myf-5 is required for the formation of skeletal muscle. Cell. 1993 Dec. 75(7), 1351-9.
- Himits Y., Willaims V., et al. Defective cranial skeletal development, larval lethality and haplosufficiency in Myod mutant Zebrafish. Developmental Biology. 2011 Oct. 358(1) 102-12.

	Temperature Limitation		In Vitro Diagnostic Medical Device
	Use By Date		Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-A21M-EN	Release Date	12-Nov-2021